Stephen Hakimi, OD
Optometrist · Pasadena, TXNPI 1285686485
Payments from drug & device makers
Across 205 payments — averaging $73.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- Alcon$3K
- Bausch & Lomb Americas Inc.$2K
- Johnson & Johnson Vision Care, Inc.$2K
- Sun Pharmaceutical Industries Inc.$1K
- AbbVie$1K
- plus $3K from 20 others
What the payments were for
- Travel & lodging$3,97726%
- Food & beverage$11,18274%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 32 | $2,971 |
| Alcon | 38 | $2,923 |
| Bausch & Lomb Americas Inc. | 27 | $2,053 |
| Johnson & Johnson Vision Care, Inc. | 14 | $1,762 |
| Sun Pharmaceutical Industries Inc. | 17 | $1,067 |
| AbbVie(2 entities) | 13 | $1,042 |
| Tarsus Pharmaceuticals, Inc. | 6 | $566 |
| Coopervision Inc. | 17 | $480 |
| Dompe US, Inc. | 3 | $279 |
| Glaukos Corporation | 2 | $247 |
| Kala Pharmaceuticals, Inc. | 4 | $177 |
| Sight Sciences, Inc. | 3 | $167 |
| Mallinckrodt Hospital Products Inc. | 3 | $160 |
| Harrow Eye, LLC | 3 | $157 |
| Amgen | 1 | $143 |
| Novartis | 2 | $140 |
| Oyster Point Pharma, Inc. | 7 | $135 |
| Biotissue Holdings Inc. | 3 | $123 |
| AstraZeneca | 1 | $122 |
| Apellis Pharmaceuticals, Inc. | 1 | $119 |
| Shire North American Group Inc | 1 | $111 |
| Optos, Inc. | 1 | $94 |
| ABB Con-cise Optical Group LLC | 1 | $36 |
| Thea Pharma Inc. | 2 | $36 |
| Rxsight Inc | 2 | $33 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BIOTRUE$1,465
- ULTRA$1,465
- Acuvue$1,439
- AIR OPTIX$1,294
- Dailies Aqua Comfort Plus$777
- CEQUA$700
- INFUSE$681
- ULTRA MULTIFOCAL TORIC$588
- MIEBO$475
- XIIDRA$468
- RESTASIS$375
- TOTAL30$356
- VUITY$349
- XDEMVY$247
- Oxervate$247
- DAILIES TOTAL1 Multifocal$245
- VYZULTA$225
- TEPEZZA$143
- TEARCARE SYSTEM$136
- Photrexa Viscous and Photrexa$135
How this compares
$15,159 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 92 | $928 |
| Latanoprost | 29 | $461 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Pasadena
- Tammi AllsepPasadena$46K
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Derek CunninghamAustin$940K
- Wendy ChungKaty$900K
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Mina VanrachackSan Antonio$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.